As insulin sensitizers, both TZDs and metformin have shown efficacy in rodent models of NASH-HCC and metformin treatment showed a small but significant improvement in survival in patients with type 2 DM and HCC in a clinical study [278,279,280]. The gene discussed is INS; the disease is hepatocellular carcinoma.